Page last updated: 2024-09-05

o-(4-ethoxybutyl)berbamine and berbamine

o-(4-ethoxybutyl)berbamine has been researched along with berbamine in 3 studies

Compound Research Comparison

Studies
(o-(4-ethoxybutyl)berbamine)
Trials
(o-(4-ethoxybutyl)berbamine)
Recent Studies (post-2010)
(o-(4-ethoxybutyl)berbamine)
Studies
(berbamine)
Trials
(berbamine)
Recent Studies (post-2010) (berbamine)
1000147165
10001108

Protein Interaction Comparison

ProteinTaxonomyo-(4-ethoxybutyl)berbamine (IC50)berbamine (IC50)
Replicase polyprotein 1abSevere acute respiratory syndrome coronavirus 27.87

Research

Studies (3)

TimeframeStudies, this research(%)All Research%
pre-19902 (66.67)18.7374
1990's0 (0.00)18.2507
2000's1 (33.33)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Liu, J; Liu, LH; Xu, YH; Zhang, SP1
Xu, YH; Zhang, SP1
Gu, Y; Ma, T; Qiu, X; Xie, J; Xu, R; Yu, Y; Zhang, L; Zhang, X1

Other Studies

3 other study(ies) available for o-(4-ethoxybutyl)berbamine and berbamine

ArticleYear
The effect of berbamine derivatives on activated Ca2+-stimulated Mg2+-dependent ATPase in erythrocyte membranes.
    The Biochemical journal, 1987, Dec-15, Volume: 248, Issue:3

    Topics: Adenosine Triphosphate; Alkaloids; Benzylisoquinolines; Binding Sites; Ca(2+) Mg(2+)-ATPase; Calcium-Transporting ATPases; Calmodulin; Enzyme Activation; Erythrocyte Membrane; Humans; Trypsin

1987
A derivative of bisbenzylisoquinoline alkaloid is a new and potential calmodulin antagonist.
    Biochemical and biophysical research communications, 1986, Oct-15, Volume: 140, Issue:1

    Topics: Alkaloids; Benzylisoquinolines; Binding Sites; Ca(2+) Mg(2+)-ATPase; Calcium; Calcium-Transporting ATPases; Calmodulin; Erythrocyte Membrane; Fluorescence; Humans; Sodium-Potassium-Exchanging ATPase

1986
Berbamine derivatives: a novel class of compounds for anti-leukemia activity.
    European journal of medicinal chemistry, 2009, Volume: 44, Issue:8

    Topics: Animals; Antineoplastic Agents; Benzamides; Benzylisoquinolines; Cell Line, Tumor; Cell Proliferation; Drug Design; Drug Resistance, Neoplasm; Humans; Imatinib Mesylate; Inhibitory Concentration 50; Leukemia; Piperazines; Pyrimidines

2009